Browsing Tag
Regenerative Medicine
33 posts
Why NCEL-101’s FDA pathway could influence the future of stem-cell-derived islet therapies
Why NewcelX Ltd.’s FDA pre-IND process for NCEL-101 could shape the future of regenerative diabetes medicine. Read the full analysis.
Can Fujifilm’s Madison iPSC facility turn stem cell science into scalable manufacturing?
iPSC demand is rising fast. Fujifilm’s Madison expansion tests whether stem cell manufacturing can keep pace with drug discovery and therapy scale-up.
Why Heart3D fusion imaging could become critical for scaling cardiac cell therapy platforms
Find out how BioCardia, Inc.’s Heart3D imaging platform could solve scalability challenges in cardiac cell therapy and reshape regenerative medicine.
What rezanecel’s durability data means for epilepsy treatment innovation
Neurona Therapeutics’ rezanecel shows durable seizure reduction. Discover what this means for epilepsy treatment innovation and future market dynamics.
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
UCB is acquiring Neurona for up to $1.15 billion to deepen its epilepsy pipeline. Read what the deal means for growth, risk, and biotech competition.
Can deeper university alliances help Propanc Biopharma, Inc. stabilize its clinical transition?
Propanc Biopharma expands university research partnerships as it enters human trials. Discover what this signals for strategy, risk, and investors.
Is this the biomarker breakthrough Longeveron Inc. needs to reach Phase 3?
Can biomarker-linked response boost laromestrocel’s Phase 3 prospects? Explore regulatory, financial, and industry implications.
Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data
Find out why Longeveron Inc.’s CEO appointment comes at a critical clinical and financial moment and what it could mean for investors and regenerative medicine.
BioStem Technologies (OTC: BSEM) acquires BioTissue wound care unit to expand hospital market presence
BioStem acquires BioTissue’s wound care business for $15M, gaining GPO access, sales force, and acute care exposure. Find out what this means for growth.
Emmecell names ex-AbbVie executive Ramin Valian as CEO to lead cell therapy platform
Emmecell names Ramin Valian as CEO to guide its magnetic cell delivery platform toward pivotal trials. Find out what this leadership shift means for the industry.